Apr 08, 2022 By Jazmine Colatriano, M.S. BioSpace Johnson & Johnson’s Janssen Pharmaceutical secured an arbitrary win regarding royalty decisions stemming from the licensing and marketing of daratumumab, an anti-CD38 monoclonal antibody treatment that has multiple indications approved by the U.S. Food and Drug Administration (FDA). The confidential arbitration was conducted by a tribunal of three earlier this […]

Sanofi is ending diabetes and cardiovascular (DCV) research efforts as part of a revamp to narrow the number of the company’s business units in the hope of bolstering growth and profit.

The Canadian province of British Columbia said its public drug plan will switch as many as 20,400 patients from three branded biologic drugs to cheap near-copies called biosimilars.

Roche aims to broaden the use of the Swiss drugmaker’s Kadcyla breast cancer treatment as rivals crowd into the market with biosimilar copies of the company’s older mainstay product Herceptin.